Project Details
Description
The TAP (Timely, Accurate and Personalised) dementia consortium aims to improve the diagnosis of Alzheimer’s disease (AD) and non-AD dementias. Particularly for the latter, including vascular cognitive impairment (VCI), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD), biomarker development has advanced less than for AD.
The project TAP-VaMP will therefore validate novel diagnostic biomarkers that:
● go beyond AD, also targeting VCI, DLB, and FTD
● improve diagnostic yield of tests that are already performed (VCI markers on MRI)
● are less invasive (blood versus CSF)
● are more accessible/less costly (fluid markers versus PET)
● can support a diagnosis of mixed-pathology
The project TAP-VaMP will therefore validate novel diagnostic biomarkers that:
● go beyond AD, also targeting VCI, DLB, and FTD
● improve diagnostic yield of tests that are already performed (VCI markers on MRI)
● are less invasive (blood versus CSF)
● are more accessible/less costly (fluid markers versus PET)
● can support a diagnosis of mixed-pathology
| Acronym | TAP-VaMP |
|---|---|
| Status | Active |
| Effective start/end date | 1/01/2023 → 1/01/2027 |